title: Comparison of the acute effects of anti-TNF-alpha drugs on a uveitis experimental model.
abstract: OBJECTIVE
  To compare histopathological and biochemical effects of the anti-TNF-alpha drugs adalimumab and infliximab in a uveitis experimental model.
  
  
  METHODS
  Histopathological evaluation was performed 24 h after endotoxin (200 microg into the footpad) and drug administration, as well as biochemical analysis of oxidative stress-related markers in the aqueous humor.
  
  
  RESULTS
  Severe inflammation was found in rat anterior chamber of the eye 24 h after endotoxin. Only infliximab administration partially prevented the endotoxin-induced disruption of the blood-aqueous barrier, as well as the increase in Rantes and MCP-1 concentration in aqueous humor. Both drugs ameliorated the histopathological score after endotoxin. Biochemical analysis revealed that both drugs protected against endotoxin-induced oxidative stress, restoring all markers to control levels, except infliximab, which failed to restore GSH concentration.
  
  
  CONCLUSIONS
  Both anti-TNF-alpha drugs were effective in reducing histopathological inflammation but their mechanism of action appears to be different.
authors.affiliation: Fundación Oftalmológica del Mediterráneo, Valencia, Spain.
authors.forename: Siv
authors.initials: S
authors.lastname: Johnsen-Soriano
authors.forename: María
authors.initials: M
authors.lastname: Sancho-Tello
authors.forename: Emma
authors.initials: E
authors.lastname: Arnal
authors.forename: Manuel
authors.initials: M
authors.lastname: Díaz-Llopis
authors.forename: Amparo
authors.initials: A
authors.lastname: Navea
authors.forename: María
authors.initials: M
authors.lastname: Miranda
authors.forename: Francisco
authors.initials: F
authors.lastname: Bosch-Morell
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Romero
mesh_terms: D000068879:Adalimumab; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001082:Aqueous Humor / Q000166:cytology / Q000378:metabolism; D018916:Blood-Aqueous Barrier / Q000502:physiology; D002478:Cells, Cultured; D004195:Disease Models, Animal; D000069285:Infliximab; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab